Heron Therapeutics (HRTX)
(Delayed Data from NSDQ)
$1.76 USD
-0.06 (-3.30%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.76 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.76 USD
-0.06 (-3.30%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.76 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Zacks News
All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy
by Zacks Equity Research
Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion
by Zacks Equity Research
Heron (HRTX) rises 19% on label expansion of its postoperative pain management drug, Zynrelef, to include additional orthopedic and soft tissue procedures.
Heron Therapeutics (HRTX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Heron Therapeutics (HRTX) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -58.82% and 4.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 25% and 24.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 32% and 13.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutical (CPRX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 4.76% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 71.43% and 14.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 2.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of -19.23% and 30.16%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Buy
by Zacks Equity Research
Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in Heron Therapeutics (HRTX)? Wall Street Analysts Think 91%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 90.6% in Heron Therapeutics (HRTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -10% and 11.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Misses Q2 Earnings Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of -1.64% and 1.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -40% and 6.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 8.47% and 20.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Heron's (HRTX) Zynrelef Gets FDA Nod for Label Expansion
by Zacks Equity Research
The FDA grants label expansion to Heron???s (HRTX) Zynrelef for pain relief after small to medium abdominal surgeries, lower extremity total joint replacements, and foot and ankle surgeries in adults.
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 15.00% and -7.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -5.08% and -21.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Heron Therapeutics (HRTX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics (HRTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -1.75% and -25.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Heron Therapeutics (HRTX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.